VivoSeq
Other

MRNA Vaccine

0

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

mRNA Vaccine is an early-stage landscape with 0 programs across 5 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Moderna, Sinovac Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalModerna logo

Moderna

0 programs

PreclinicalSinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd

0 programs

PreclinicalA

Argorna Pharmaceuticals Co., LTD

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Unknown status8 · 53%
Completed3 · 20%
Not yet recruiting3 · 20%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
Active, not recruiting·Sanofi logoSanofi·Phase 1/2·NCT06891417·1,560 enrolled
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
Not yet recruiting·RRuijin Hospital·Phase 1·NCT07334574·20 enrolled
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
Not yet recruiting·AAkeso·Phase 1·NCT06913218·60 enrolled
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
Not yet recruiting·Sinovac Biotech Co., Ltd logoSinovac Biotech Co., Ltd·Phase 1·NCT07418229·60 enrolled
A Study of Modified mRNA Vaccines in Healthy Adults
Completed·Moderna logoModerna·Phase 1·NCT05397223·308 enrolled
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
Completed·NNovavax·Phase 3·NCT05875701·147 enrolled
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
Completed·AArgorna Pharmaceuticals Co., LTD·Phase 1/2·NCT05903118·480 enrolled
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
Unknown status·AAIM Vaccine Co., Ltd.·N/A·NCT05550142·54 enrolled
Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older
Unknown status·AAIM Vaccine Co., Ltd.·Phase 3·NCT05812014·9,800 enrolled
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
Unknown status·AAIM Vaccine Co., Ltd.·Phase 1·NCT05599802·144 enrolled
Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine
Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04900467·418 enrolled
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
Unknown status·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05439824·450 enrolled
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
Unknown status·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05354089·40 enrolled
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
Unknown status·AAIM Vaccine Co., Ltd.·N/A·NCT05549206·350 enrolled
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
Unknown status·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05354063·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)